IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Providence Capital Advisors LLC

Providence Capital Advisors LLC lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 22,264 shares of the medical research company’s stock after purchasing an additional 173 shares during the quarter. Providence Capital Advisors LLC’s holdings in IQVIA were worth $4,375,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Synergy Asset Management LLC purchased a new position in shares of IQVIA in the 4th quarter valued at $33,000. Lee Danner & Bass Inc. acquired a new stake in shares of IQVIA in the fourth quarter valued at about $44,000. Zions Bancorporation N.A. raised its holdings in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after buying an additional 85 shares during the period. Versant Capital Management Inc lifted its position in IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after acquiring an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in IQVIA in the fourth quarter valued at approximately $60,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on IQV shares. Truist Financial reaffirmed a “buy” rating and set a $263.00 price target (up from $261.00) on shares of IQVIA in a report on Monday, February 10th. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Citigroup dropped their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Stephens started coverage on shares of IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price target for the company. Finally, JPMorgan Chase & Co. cut their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Stock Performance

Shares of NYSE IQV opened at $179.40 on Friday. IQVIA Holdings Inc. has a 12-month low of $176.74 and a 12-month high of $253.84. The company has a market cap of $31.63 billion, a PE ratio of 23.92, a P/E/G ratio of 1.99 and a beta of 1.50. The stock has a 50 day simple moving average of $193.55 and a 200-day simple moving average of $206.91. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.